800 results on '"Caldwell, Stephen H."'
Search Results
202. Effects of restoring portal flow with anticoagulation and partial splenorenal shunt embolization
203. Treating thrombosis in cirrhosis patients with new oral agents: Ready or not?
204. A Case of Retinal Tear Associated with Use of Sorafenib
205. Management of disordered hemostasis and coagulation in patients with cirrhosis
206. Mo1012 Characteristics of Cirrhotic Patients With Concomitant Portal Vein Thrombosis and Non-Splanchnic Venous Thromboembolism
207. Direct acting inhibitors of ammoniagenesis: a role in post-TIPS encephalopathy?
208. Bilirubin alone as a biomarker for short-term mortality in acute-on-chronic liver failure: an important prognostic indicator
209. Prophylactic anticoagulation for venous thromboembolism in hospitalized cirrhosis patients is not associated with high rates of gastrointestinal bleeding
210. Practice patterns in NAFLD and NASH: real life differs from published guidelines.
211. Bleeding and thrombosis in cirrhotic patients: What really matters?
212. Nonalcoholic Fatty Liver Disease
213. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant
214. Implementing a Treatment Protocol Reduces Inpatient Cost of Hepatic Encephalopathy
215. Bleeding Gastric Varices Obliteration with Balloon-occluded Retrograde Transvenous Obliteration Using Sodium Tetradecyl Sulfate Foam
216. FACTORS AFFECTING PATIENT COMPLIANCE WITH DIAGNOSTIC RECOMMENDATIONS
217. Hemostasis and thrombosis in patients with liver disease: The ups and downs
218. Clinical physiology of NAFLD: a critical overview of pathogenesis and treatment
219. S1292 Sorafenib in Combination With Locoregional Therapy for Hepatocellular Carcinoma in Patients on the Liver Transplant Waiting List: One Center's Experience
220. New concepts of coagulation and bleeding in liver disease
221. Epidemiology and Natural History of Non-Alcoholic Steatohepatitis
222. Endoscopic cyanoacrylate versus transjugular intrahepatic portosystemic shunt for gastric variceal bleeding: a single-center U.S. analysis
223. NASH and cryptogenic cirrhosis: A histological analysis
224. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
225. Thiazolidinediones for the Treatment in NASH
226. Reply
227. W1774 Cost Effectiveness of Radiofrequency Ablation Versus Transcatheter Arterial Chemoembolization in Patients with Hepatocellular Carcinoma Less Than 4.5 CM in Diameter
228. 260 The Use of Thromboelastography, Platelets, and INR in a Clinical Model for Bleeding Risk in Cirrhotic Patients
229. Preface
230. The Role of Anti-Fibrinolytics, rFVIIa and Other Pro-Coagulants: Prophylactic Versus Rescue?
231. Coagulation Disorders and Bleeding in Liver Disease: Future Directions
232. Intramitochondrial crystalline inclusions in nonalcoholic steatohepatitis
233. Expression of Perilipin and Adipophilin in Nonalcoholic Fatty Liver Disease; Relevance to Oxidative Injury and Hepatocyte Ballooning
234. Propensity for non-alcoholic fatty liver disease: more evidence for ethnic susceptibility
235. Variation between centers in technique and guidelines for liver biopsy
236. A rodent model of NASH with cirrhosis, oval cell proliferation and hepatocellular carcinoma
237. Liver biopsy
238. Statins in liver disease: A molehill, an iceberg, or neither?
239. AASLD position paper: Liver biopsy
240. Intensive care of patients with acute liver failure: Recommendations of the U.S. Acute Liver Failure Study Group
241. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis
242. Has natural selection in human populations produced two types of metabolic syndrome (with and without fatty liver)?
243. The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis
244. Divergent effects of peroxisome proliferator–activated receptor-γ ligands in human and mouse nonalcoholic steatohepatitis
245. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups.
246. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis.
247. The Prevalence of Spur Cell Anemia in Hospitalized Cirrhotics and Its Relationship to Coagulation, Hemolysis and HDL Cholesterol
248. Severe Prolongation of the INR in Spur Cell Anemia of Cirrhosis: True-True and Related?
249. How useful is ε-aminocaproic acid for the treatment of hyperfibrinolysis in patients with cirrhosis?
250. Reply
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.